Compositions and methods of delivery of pharmacological agents

Abstract

The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. He human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The inventor also provides methods for reducing on or more side effects of administration of the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.

1 . (canceled) 
     
     
         2 . A method for enhancing transport of a pharmaceutical agent to the site of an infirmity, which method comprises administering to a human a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier comprises albumin, and wherein the ratio of albumin to pharmaceutical agent in the pharmaceutical composition is about 18:1 or less. 
     
     
         3 - 5 . (canceled) 
     
     
         6 . The method of  claim 2 , wherein the pharmaceutical composition is a liquid and comprises from about 0.1% to about 25% by weight of albumin. 
     
     
         7 . The method of  claim 6 , wherein the pharmaceutical composition comprises about 0.5% to about 5% by weight of albumin. 
     
     
         8 - 9 . (canceled) 
     
     
         10 . The method of  claim 2 , wherein the ratio of albumin to pharmaceutical agent in the pharmaceutical composition is about 12:1 or less. 
     
     
         11 . The method of  claim 2 , wherein the ratio of albumin to pharmaceutical agent in the pharmaceutical composition is about 9:1 or less. 
     
     
         12 . The method of  claim 2 , wherein the pharmaceutical composition is administered to the human via intravenous administration, intra-arterial administration, intrapulmonary administration, oral administration, inhalation, intra-tracheal administration, intravesicular administration, intramuscular administration, subcutaneous administration, intraocular administration, intrathecal administration, or transdermal administration. 
     
     
         13 - 23 . (canceled) 
     
     
         24 . A pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier comprises albumin in an amount effective to increase transport of the drug to the site of infirmity in a human, or in an amount effective to reduce one or more side effects of administration of the pharmaceutical composition into a human, and wherein the ratio of albumin to pharmaceutical agent is about 18:1 or less. 
     
     
         25 . The pharmaceutical composition of  claim 24 , wherein the ratio of albumin to pharmaceutical agent in the pharmaceutical composition is about 12:1 or less. 
     
     
         26 . The pharmaceutical composition of  claim 24 , wherein the ratio of albumin to pharmaceutical agent in the pharmaceutical composition is about 9:1 or less. 
     
     
         27 . The pharmaceutical composition of  claim 24 , wherein the infirmity is selected from the group consisting of cancer, arthritis, and cardiovascular disease. 
     
     
         28 - 34 . (canceled) 
     
     
         35 . A pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier comprises a protein in an amount effective to reduce one or more side effects of administration of the pharmaceutical composition into a human, and wherein the ratio of protein to pharmaceutical agent is about 18:1 or less. 
     
     
         36 . The pharmaceutical composition of  claim 35 , wherein the ratio of protein to pharmaceutical agent in the pharmaceutical composition is about 12:1 or less. 
     
     
         37 . The pharmaceutical composition of  claim 35 , wherein the ratio of protein to pharmaceutical agent in the pharmaceutical composition is about 9:1 or less.